A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 1,316,590 shares of NBIX stock, worth $162 Million. This represents 2.82% of its overall portfolio holdings.

Number of Shares
1,316,590
Previous 691,004 90.53%
Holding current value
$162 Million
Previous $95.1 Million 59.34%
% of portfolio
2.82%
Previous 2.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$114.58 - $153.15 $71.7 Million - $95.8 Million
625,586 Added 90.53%
1,316,590 $152 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $26.8 Million - $29.6 Million
-205,715 Reduced 22.94%
691,004 $95.3 Million
Q4 2023

Feb 14, 2024

SELL
$106.07 - $132.76 $33.2 Million - $41.6 Million
-312,995 Reduced 25.87%
896,719 $118 Million
Q2 2023

Aug 14, 2023

SELL
$89.53 - $104.87 $47.9 Million - $56.1 Million
-535,000 Reduced 30.66%
1,209,714 $114 Million
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $21.8 Million - $28.5 Million
232,000 Added 15.34%
1,744,714 $177 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $46 Million - $53.9 Million
-500,000 Reduced 24.84%
1,512,714 $161 Million
Q2 2022

Aug 15, 2022

BUY
$75.79 - $100.07 $26.9 Million - $35.5 Million
354,914 Added 21.41%
2,012,714 $196 Million
Q1 2022

May 16, 2022

BUY
$72.45 - $94.81 $20.3 Million - $26.5 Million
279,855 Added 20.31%
1,657,800 $155 Million
Q4 2021

Feb 14, 2022

BUY
$79.65 - $106.22 $18.8 Million - $25 Million
235,530 Added 20.62%
1,377,945 $117 Million
Q3 2021

Nov 15, 2021

BUY
$86.18 - $99.03 $36 Million - $41.3 Million
417,415 Added 57.57%
1,142,415 $110 Million
Q1 2021

May 17, 2021

BUY
$87.57 - $119.4 $63.5 Million - $86.6 Million
725,000 New
725,000 $70.5 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.8B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.